natgillin/translations-raw huggingface dataset:
ViraferonPeg 50 micrograms powder and solvent for solution for injection pre-filled pen peginterferon alfa-2b
ViraferonPeg 50 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem peresniku peginterferon alfa- 2b
One ViraferonPeg pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide 50 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.
En napolnjen peresnik zdravila ViraferonPeg vsebuje zadostno količino peginterferona alfa- 2b za dajanje 50 mikrogramov v 0, 5 ml peginterferona alfa- 2b po rekonstituciji v skladu s priporočili.
Excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose and polysorbate 80.
Pomožne snovi: natrijev fosfat, brezvodni; natrijev dihidrogen fosfat dihidrat, saharoza in polisorbat 80.
1 pen, 1 injection needle and 2 cleansing swabs 4 pens, 4 injection needles and 8 cleansing swabs 6 pens, 6 injection needles and 12 cleansing swabs 12 pens, 12 injection needles and 24 cleansing swabs 50 micrograms/0.5 ml
1 peresnik, 1 injekcijska igla in 2 čistilna tampona 4 peresniki, 4 injekcijske igle in 8 čistilnih tamponov 6 peresnikov, 6 injekcijskih igel in 12 čistilnih tamponov 12 peresnikov, 12 injekcijskih igel in 24 čistilnih tamponov 50 mikrogramov/ 0, 5 ml
252 9.
260 9.
EU/1/00/132/031 (1 pen, 1 injection needle and 2 cleansing swabs) EU/1/00/132/032 (4 pens, 4 injection needles and 8 cleansing swabs) EU/1/00/132/033 (6 pens, 6 injection needles and 12 cleansing swabs) EU/1/00/132/034 (12 pens, 12 injection needles and 24 cleansing swabs)
EU/ 1/ 00/ 132/ 031 (1 peresnik, 1 injekcijska igla in 2 čistilna tampona) EU/ 1/ 00/ 132/ 032 (4 peresniki, 4 injekcijske igle in 8 čistilnih tamponov) EU/ 1/ 00/ 132/ 033 (6 peresnikov, 6 injekcijskih igel in 12 čistilnih tamponov) EU/ 1/ 00/ 132/ 034 (12 peresnikov, 12 injekcijskih igel in 24 čistilnih tamponov)
253 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
261 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
ViraferonPeg 50 micrograms powder and solvent for injection SC
ViraferonPeg 50 mikrogramov prašek in vehikel za raztopino za injiciranje s. c.
254 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
262 PODATKI NA ZUNANJI OVOJNINI
Carton 80 micrograms powder and solvent for solution for injection
Škatla 80 mikrogramov prašek in vehikel za raztopino za injiciranje
ViraferonPeg 80 micrograms powder and solvent for solution for injection pre-filled pen peginterferon alfa-2b
ViraferonPeg 80 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem peresniku peginterferon alfa- 2b
One ViraferonPeg pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide 80 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.
En napolnjen peresnik zdravila ViraferonPeg vsebuje zadostno količino peginterferona alfa- 2b za dajanje 80 mikrogramov v 0, 5 ml peginterferona alfa- 2b po rekonstituciji v skladu s priporočili.
1 pen, 1 injection needle and 2 cleansing swabs 4 pens, 4 injection needles and 8 cleansing swabs 6 pens, 6 injection needles and 12 cleansing swabs 12 pens, 12 injection needles and 24 cleansing swabs 80 micrograms/0.5 ml
1 peresnik, 1 injekcijska igla in 2 čistilna tampona 4 peresniki, 4 injekcijske igle in 8 čistilnih tamponov 6 peresnikov, 6 injekcijskih igel in 12 čistilnih tamponov 12 peresnikov, 12 injekcijskih igel in 24 čistilnih tamponov 80 mikrogramov/ 0, 5 ml
255 9.
263 9.
EU/1/00/132/035 (1 pen, 1 injection needle and 2 cleansing swabs) EU/1/00/132/036 (4 pens, 4 injection needles and 8 cleansing swabs) EU/1/00/132/037 (6 pens, 6 injection needles and 12 cleansing swabs) EU/1/00/132/038 (12 pens, 12 injection needles and 24 cleansing swabs)
EU/ 1/ 00/ 132/ 035 (1 peresnik, 1 injekcijska igla in 2 čistilna tampona) EU/ 1/ 00/ 132/ 036 (4 peresniki, 4 injekcijske igle in 8 čistilnih tamponov) EU/ 1/ 00/ 132/ 037 (6 peresnikov, 6 injekcijskih igel in 12 čistilnih tamponov) EU/ 1/ 00/ 132/ 038 (12 peresnikov, 12 injekcijskih igel in 24 čistilnih tamponov)
256 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
264 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
ViraferonPeg 80 micrograms powder and solvent for injection SC
ViraferonPeg 80 mikrogramov prašek in vehikel za raztopino za injiciranje s. c.
257 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
265 PODATKI NA ZUNANJI OVOJNINI
Carton 100 micrograms powder and solvent for solution for injection
Škatla 100 mikrogramov prašek in vehikel za raztopino za injiciranje
ViraferonPeg 100 micrograms powder and solvent for solution for injection pre-filled pen peginterferon alfa-2b
ViraferonPeg 100 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem peresniku peginterferon alfa- 2b
One ViraferonPeg pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide 100 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.
En napolnjen peresnik zdravila ViraferonPeg vsebuje zadostno količino peginterferona alfa- 2b za dajanje 100 mikrogramov v 0, 5 ml peginterferona alfa- 2b po rekonstituciji v skladu s priporočili.
1 pen, 1 injection needle and 2 cleansing swabs 4 pens, 4 injection needles and 8 cleansing swabs 6 pens, 6 injection needles and 12 cleansing swabs 12 pens, 12 injection needles and 24 cleansing swabs 100 micrograms/0.5 ml
1 peresnik, 1 injekcijska igla in 2 čistilna tampona 4 peresniki, 4 injekcijske igle in 8 čistilnih tamponov 6 peresnikov, 6 injekcijskih igel in 12 čistilnih tamponov 12 peresnikov, 12 injekcijskih igel in 24 čistilnih tamponov 100 mikrogramov/ 0, 5 ml
258 9.
266 9.
EU/1/00/132/039 (1 pen, 1 injection needle and 2 cleansing swabs) EU/1/00/132/040 (4 pens, 4 injection needles and 8 cleansing swabs) EU/1/00/132/041 (6 pens, 6 injection needles and 12 cleansing swabs) EU/1/00/132/042 (12 pens, 12 injection needles and 24 cleansing swabs)
EU/ 1/ 00/ 132/ 039 (1 peresnik, 1 injekcijska igla in 2 čistilna tampona) EU/ 1/ 00/ 132/ 040 (4 peresniki, 4 injekcijske igle in 8 čistilnih tamponov) EU/ 1/ 00/ 132/ 041 (6 peresnikov, 6 injekcijskih igel in 12 čistilnih tamponov) EU/ 1/ 00/ 132/ 042 (12 peresnikov, 12 injekcijskih igel in 24 čistilnih tamponov)
259 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
267 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
ViraferonPeg 100 micrograms powder and solvent for injection SC
ViraferonPeg 100 mikrogramov prašek in vehikel za raztopino za injiciranje s. c.
260 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
268 PODATKI NA ZUNANJI OVOJNINI
Carton 120 micrograms powder and solvent for solution for injection
Škatla 120 mikrogramov prašek in vehikel za raztopino za injiciranje
ViraferonPeg 120 micrograms powder and solvent for solution for injection pre-filled pen peginterferon alfa-2b
ViraferonPeg 120 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem peresniku peginterferon alfa- 2b
One ViraferonPeg pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide 120 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.
En napolnjen peresnik zdravila ViraferonPeg vsebuje zadostno količino peginterferona alfa- 2b za dajanje 120 mikrogramov v 0, 5 ml peginterferona alfa- 2b po rekonstituciji v skladu s priporočili.
1 pen, 1 injection needle and 2 cleansing swabs 4 pens, 4 injection needles and 8 cleansing swabs 6 pens, 6 injection needles and 12 cleansing swabs 12 pens, 12 injection needles and 24 cleansing swabs 120 micrograms/0.5 ml
1 peresnik, 1 injekcijska igla in 2 čistilna tampona 4 peresniki, 4 injekcijske igle in 8 čistilnih tamponov 6 peresnikov, 6 injekcijskih igel in 12 čistilnih tamponov 12 peresnikov, 12 injekcijskih igel in 24 čistilnih tamponov 120 mikrogramov/ 0, 5 ml
261 9.
269 9.
EU/1/00/132/043 (1 pen, 1 injection needle and 2 cleansing swabs) EU/1/00/132/044 (4 pens, 4 injection needles and 8 cleansing swabs) EU/1/00/132/045 (6 pens, 6 injection needles and 12 cleansing swabs) EU/1/00/132/046 (12 pens, 12 injection needles and 24 cleansing swabs)
EU/ 1/ 00/ 132/ 043 (1 peresnik, 1 injekcijska igla in 2 čistilna tampona) EU/ 1/ 00/ 132/ 044 (4 peresniki, 4 injekcijske igle in 8 čistilnih tamponov) EU/ 1/ 00/ 132/ 045 (6 peresnikov, 6 injekcijskih igel in 12 čistilnih tamponov) EU/ 1/ 00/ 132/ 046 (12 peresnikov, 12 injekcijskih igel in 24 čistilnih tamponov)
262 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
270 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
ViraferonPeg 120 micrograms powder and solvent for injection SC
ViraferonPeg 120 mikrogramov prašek in vehikel za raztopino za injiciranje s. c.
263 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
271 PODATKI NA ZUNANJI OVOJNINI
Carton 150 micrograms powder and solvent for solution for injection
Škatla 150 mikrogramov prašek in vehikel za raztopino za injiciranje
ViraferonPeg 150 micrograms powder and solvent for solution for injection pre-filled pen peginterferon alfa-2b
ViraferonPeg 150 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem peresniku peginterferon alfa- 2b
One ViraferonPeg pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide 150 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.
En napolnjen peresnik zdravila ViraferonPeg vsebuje zadostno količino peginterferona alfa- 2b za dajanje 150 mikrogramov v 0, 5 ml peginterferona alfa- 2b po rekonstituciji v skladu s priporočili.
1 pen, 1 injection needle and 2 cleansing swabs 4 pens, 4 injection needles and 8 cleansing swabs 6 pens, 6 injection needles and 12 cleansing swabs 12 pens, 12 injection needles and 24 cleansing swabs 150 micrograms/0.5 ml
1 peresnik, 1 injekcijska igla in 2 čistilna tampona 4 peresniki, 4 injekcijske igle in 8 čistilnih tamponov 6 peresnikov, 6 injekcijskih igel in 12 čistilnih tamponov 12 peresnikov, 12 injekcijskih igel in 24 čistilnih tamponov 150 mikrogramov/ 0, 5 ml
264 9.
272 9.
EU/1/00/132/047 (1 pen, 1 injection needle and 2 cleansing swabs) EU/1/00/132/048 (4 pens, 4 injection needles and 8 cleansing swabs) EU/1/00/132/049 (6 pens, 6 injection needles and 12 cleansing swabs) EU/1/00/132/050 (12 pens, 12 injection needles and 24 cleansing swabs)
EU/ 1/ 00/ 132/ 047 (1 peresnik, 1 injekcijska igla in 2 čistilna tampona) EU/ 1/ 00/ 132/ 048 (4 peresniki, 4 injekcijske igle in 8 čistilnih tamponov) EU/ 1/ 00/ 132/ 049 (6 peresnikov, 6 injekcijskih igel in 12 čistilnih tamponov) EU/ 1/ 00/ 132/ 050 (12 peresnikov, 12 injekcijskih igel in 24 čistilnih tamponov)
265 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
273 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
ViraferonPeg 150 micrograms powder and solvent for injection SC
ViraferonPeg 150 mikrogramov prašek in vehikel za raztopino za injiciranje s. c.
266 B.
274 B.
INFORMATION FOR THE USER
275 NAVODILO ZA UPORABO
ViraferonPeg 50 micrograms powder and solvent for solution for injection peginterferon alfa-2b (conjugation of recombinant interferon alfa-2b with monomethoxy polyethylene glycol)
ViraferonPeg 50 mikrogramov prašek in vehikel za raztopino za injiciranje peginterferon alfa- 2b (konjugat rekombinantnega interferona alfa- 2b z monometoksipolietilenglikolom)
What ViraferonPeg is and what it is used for 2.
Kaj je zdravilo ViraferonPeg in za kaj ga uporabljamo 2.
Before you use ViraferonPeg 3.
Kaj morate vedeti, preden boste uporabili zdravilo ViraferonPeg 3.
How to use ViraferonPeg 4.
Kako uporabljati zdravilo ViraferonPeg 4.
How to store ViraferonPeg 6.
Shranjevanje zdravila ViraferonPeg 6.
WHAT VIRAFERONPEG IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO VIRAFERONPEG IN ZA KAJ GA UPORABLJAMO
Interferons modify the response of the body's immune system to help fight infections and severe diseases.
Interferoni spreminjajo odziv telesnega imunskega sistema in pomagajo premagovati okužbe in hude bolezni.
ViraferonPeg, which contains an interferon, is used for the treatment of chronic hepatitis C, a viral infection of the liver, including in first time users co-infected with clinically stable HIV.
ViraferonPeg, ki vsebuje enega od interferonov, se uporablja za zdravljenje kroničnega hepatitisa C, ene od virusnih okužb jeter, vključno z osebami, ki imajo sočasno klinično stabilno okužbo z virusom HIV in zdravilo uporabljajo prvič.
ViraferonPeg is best used for this treatment in combination with ribavirin.
Za to zdravljenje je najbolje uporabljati zdravilo ViraferonPeg v kombinaciji z ribavirinom.
This combination is indicated in first -time users.
Kombinirano zdravljeneje je indicirano pri bolnikih, ki prvič jemljejo to zdravilo.
This combination is also indicated in relapse patients and patients who have not responded previously to interferon alpha (pegylated or nonpegylated) and ribavirin combination therapy or interferon alpha monotherapy.
Ta kombinacija je indicirana tudi pri bolnikih s ponovnim izbruhom bolezni in pri tistih, ki se predhodno niso odzvali na kombinirano terapijo z interferonom alfa (pegiliranim ali nepegiliranim) in ribavirinom ali na monoterapijo z interferonom alfa.
ViraferonPeg is used alone in case of intolerance or contraindication to ribavirin.
ViraferonPeg se uporablja samostojno v primeru, da ga bolniki ne prenašajo ali da obstajajo kontraindikacije za uporabo ribavirina.
BEFORE YOU USE VIRAFERONPEG
KAJ MORATE VEDETI, PREDEN BOSTE UPORABILI ZDRAVILO VIRAFERONPEG
ViraferonPeg is not recommended for use in patients under the age of 18 years.
Zdravilo ViraferonPeg ni priporočljivo za uporabo pri bolnikih, mlajših od 18 let.
- If you are allergic (hypersensitive) to peginterferon alfa-2b or any of the other ingredients of
- če ste alergični (preobčutljivi) na peginterferon alfa- 2b ali za katerokoli sestavino zdravila
ViraferonPeg.
ViraferonPeg,
- If you are allergic (hypersensitive) to any interferon.
- če ste alergični na (preobčutljivi za) katerikoli interferon,
- If you have had severe heart problems, or if you have heart disease that has not been well controlled
- če ste kdaj imeli hude težave s srcem, ali če imate srčno bolezen, ki se ga v zadnjih 6 mesecih ni
during the past 6 months.
bilo mogoče dobro nadzorovati,
- If you have s evere medical conditions that leave you very weak.
- če imate kako hujšo bolezen, zaradi katere se počutite zelo šibki,
- If you have autoimmune hepatitis or any other problem with your immune system; if you are
- če imate avtoimunski hepatitis ali kakršnekoli druge težave z imunskim sistemom; če jemljete
taking medicine that suppresses your immune system (your immune system protects you against infection and some diseases).
zdravila, ki zavirajo imunski sistem (imunski sistem varuje telo pred okužbami in nekaterimi boleznimi),
- If you have advanced, uncontrolled liver disease (other than hepatitis C).
- če imate napredovalo nenadzorovano jetrno bolezen (razen hepatitisa C),
- If you have thyroid disease that is not well controlled with medicines.
- če imate ščitnično bolezen, ki je z zdravili ni možno dobro nadzorovati,
- If you have a condition that causes convulsions (seizures, or “fits”).
- če imate bolezen, ki povzroča napade konvulzije (epileptične krče ali podobne napade).
268 Take special care with ViraferonPeg
Bodite posebno pozorni pri uporabi zdravila ViraferonPeg
- If you develop symptoms of a severe allergic reaction (such as difficulty in breathing, wheezing, or
- če se med jemanjem tega zdravila pojavijo simptomi hude alergijske reakcije (npr. težave z
hives) while on this medication, seek medical help immediately.
dihanjem, piskanje v pljučih ali koprivnica), nemudoma poiščite zdravniško pomoč,
- If you ever had a heart attack or a heart problem.
- če ste kdaj imeli srčni infarkt ali težave s srcem,
- If you have ever been treated for depression or any other nervous or mental disorder.
- če ste se kdaj zdravili zaradi depresije ali kakšne druge živčne ali duševne motnje,
- If you have kidney disease, your doctor may prescribe a lower than usual dose and monitor your
- če imate ledvično bolezen, vam bo zdravnik morda predpisal manjši odmerek od običajnega in bo
If you have a kidney disease and you are using ViraferonPeg in combination with medicinal products containing ribavirin, your doctor should monitor you more carefully for a decrease in red blood cell count.
med zdravljenjem redno spremljal ledvične parametre v vaši krvi; če imate ledvično bolezen in uporabljate zdravilo ViraferonPeg v kombinaciji z zdravili, ki vsebujejo ribavirin, vas bo moral vaš zdravnik bolj skrbno spremljati, da ugotovi morebitno zmanjšanje števila rdečih krvničk;
- If you have had a problem with your liver (other than hepatitis C).
- če ste kdaj imeli težave z jetri (razen hepatitisa C),
- If you develop symptoms associated with a cold or other respiratory infection, such as fever, cough,
- če dobite simptome prehlada ali druge okužbe dihal, npr. zvišana telesna temperatura, kašelj ali
or any difficulty in breathing, tell your doctor.
kakršnekoli težave z dihanjem, to povejte svojemu zdravniku,
- If you are diabetic, your doctor may ask you to have an eye examination.
- če imate sladkorno bolezen, vas bo zdravnik morda napotil na pregled oči,
- If you have had any serious illness affecting your breathing or your blood.
- če ste imeli kakršnokoli resno bolezen, ki je vplivala na dihanje ali kri,
- If you have psoriasis, it may become worse while you are using ViraferonPeg.
- če imate psoriazo, se ta lahko poslabša med uporabo zdravila ViraferonPeg,
- If you are planning to become pregnant, discuss this with your doctor before starting to use
- če načrtujete nosečnost, se o tem pogovorite s svojim zdravnikom pred začetkom zdravljenja z
ViraferonPeg.
zdravilom ViraferonPeg,
- If you are also being treated for HIV, please see Using other medicines.
- če se zdravite tudi zaradi okužbe s HIV, glejte poglavje Jemanje drugih zdravil,
- If you have had a severe nervous or mental disorder.
- če ste imeli kdaj v preteklosti hudo bolezen živčevja ali duševno bolezen,
- If you ever had depression or develop symptoms associated with depression (e.g. feelings of
- če ste kdaj imeli depresijo ali če se pri vas pojavijo simptomi, povezani z depresijo (npr.
sadness, dejection, etc) while on treatment with ViraferonPeg (see section 4).
žalostno razpoloženje, občutki potrtosti in malodušnosti, ipd.) med zdravljenjem z zdravilom ViraferonPeg (glejte poglavje 4),
- If you have received an organ transplant, either kidney or liver, interferon treatment may increase
- če imate presajen organ, bodisi jetra ali ledvico, lahko zdravljenje z interferonom poveča tveganje
the risk of rejection.
za zavrnitev presajenega organa.
Dental and gum disorders, which may lead to loss of teeth, have been reported in patients receiving ViraferonPeg and ribavirin combination therapy.
Pri bolnikih, ki so prejemali zdravilo ViraferonPeg in ribavirin v kombinirani terapiji, so poročali o zobnih boleznih in boleznih parodoncija, ki lahko vodijo do izgube zob.
In addition, dry mouth could have a damaging effect on teeth and membranes of the mouth during long -term treatment with the combination of ViraferonPeg with ribavirin.
Poleg tega bi lahko med dolgotrajnim zdravljenjem s kombinacijo zdravila ViraferonPeg in ribavirina imela škodljiv vpliv na zobe in ustno sluznico tudi suha usta.
While being treated with ViraferonPeg Your doctor may want you to drink extra fluids to help prevent low blood pressure.
Med zdravljenjem z zdravilom ViraferonPeg Vaš zdravnik vam bo lahko naročil, da pijte veliko tekočine, da bi preprečili pojav nizkega krvnega tlaka.
Using other medicines Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, even those not prescribed.
Uporaba drugih zdravil Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
In combination therapy with ribavirin, ribavirin can be very damaging to an unborn baby, thus both female and male patients must take special precautions in their sexual activity if there is any chance for pregnancy to occur:
Pri kombinirani terapiji z ribavirinom, je ribavirin lahko zelo škodljiv za plod, zato morajo tako bolnice kot bolniki upoštevati posebne previdnostne ukrepe glede spolnih odnosov, če obstaja kakršnakoli možnost za zanositev:
If you are a male patient, you and your partner must each use an effective contraceptive during the time you are taking ribavirin and for 7 months after stopping treatment.
Če ste moški, morata tako vi kot vaša partnerka uporabljati učinkovito kontracepcijsko sredstvo v času
269 It is not known whether this product is present in human milk.
Ni znano, ali je to zdravilo prisotno v materinem mleku pri človeku.
Therefore, do not breast-feed an infant if you are taking ViraferonPeg.
Če se zdravite s zdravilom ViraferonPeg, torej ne smete dojiti.
In combination therapy with ribavirin, take notice of the respective informing texts of ribavirin containing medicinal products.
Pri kombinirani terapiji z ribavirinom morate upoštevati ustrezna informativna besedila za zdravila, ki vsebujejo ribavirin.
Driving and using machines Do not drive or operate any tools or machines if you feel tired, sleepy or confused while taking ViraferonPeg.
Vpliv na sposobnost upravljanja vozil in strojev Če ste med zdravljenjem z zdravilom ViraferonPeg utrujeni, zaspani ali zmedeni, ne vozite in ne delajte z orodji ali stroji.
Important information about some of the ingredients of ViraferonPeg This medicinal product contains less than 1 mmol sodium (23 mg) per 0.7 ml, i.e., essentially "sodium-free".
Pomembne informacije o nekaterih sestavinah zdravila ViraferonPeg To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na 0, 7 ml, t. j. praktično ne vsebuje natrija.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Če vam je vaš zdravnik povedal, da ne prenašate določenih sladkorjev, se posvetujte z njim, preden začnete jemati to zdravilo.
Patients who also have HIV infection Lactic acidosis and worsening liver function are side effects associated with Highly Active Anti- Retroviral Therapy (HAART), an HIV treatment.
Laktacidoza in poslabšanje delovanja jeter so neželeni učinki, povezani z visoko aktivno antiretrovirusno terapijo (HAART), vrsto zdravljenja okužbe z virusom HIV.
If you are receiving HAART, the addition of ViraferonPeg and ribavirin may increase your risk of lactic acidosis and of liver failure.
Če prejemate HAART, lahko dodajanje zdravila ViraferonPeg in ribavirina poveča tveganje za pojav laktacidoze in jetrne okvare.
Your doctor will monitor you for signs and symptoms of these conditions (Please be sure to read the ribavirin Patient Leaflet also).
Vaš zdravnik vas bo spremljal, da ugotovi morebitne znake in simptome teh stanj (vsekakor morate prebrati tudi navodilo za uporabo za ribavirin).
Additionally, patients treated with ViraferonPeg and ribavirin combination therapy and zidovudine could be at increased risk of developing anaemia (low number of red blood cells).
Pri bolnikih zdravljenih z zdravilom ViraferonPeg v kombinaciji z ribavirinom in zidovudinom, se lahko dodatno poveča verjetnost za razvoj anemije (majhno število rdečih krvnih celic).
If you are also being treated for Human Immunodeficiency Virus (HIV) infection (AIDS) with zidovudine or stavudine, it is not certain if ribavirin will change the way these medicines work.
Če se zdravite tudi zaradi okužbe z virusom imunskega pomanjkanja pri človeku (HIV) oziroma zaradi AIDS- a z zidovudinom ali stavudinom, bi ribavirin lahko spremenil način delovanja teh dveh zdravil.
Therefore, your blood will be checked regularly to be sure that the HIV infection is not getting worse.
Zato bodo morali pri vas redno opravljati krvne preiskave, da preverijo, ali se vam ne poslabšuje okužba z virusom HIV.
If it gets worse, your doctor will decide whether or not your ribavirin treatment needs to be changed.
Če se stanje poslabša, se bo zdravnik odločil, ali je pri vas potrebno spremeniti zdravljenje z ribavirinom ali ne.